Literature DB >> 29881806

Expanding spectrum of RARS2 gene disorders: Myoclonic epilepsy, mental retardation, spasticity, and extrapyramidal features.

Thomas Mathew1, Amrutha Avati1, Delon D'Souza1, Manjusha Therambil1.   

Abstract

Pontocerebellar hypoplasia type 6 (PCH6) is an autosomal recessive mitochondrial disease, typically characterized by pontine atrophy, vermian hypoplasia, infantile encephalopathy, generalized hypotonia, and intractable seizures. The purpose of this study is to describe the seizures and other neurological manifestations of RARS2 gene mutations and to compare the clinical features with other causes of progressive myoclonic epilepsy. Detailed history, physical examination, and clinical and genetic work-up were performed in 2 siblings who presented with progressive myoclonic epilepsy. One sibling, a 20-year-old woman, and the other a 24-year-old man, had a homozygous missense variant (c.848T>A; p.Leu283Gln) in exon 10 of the RARS2 gene. The female patient had action and audiogenic myoclonic jerks, postural tremors, spastic dysarthria, and bradykinesia, and her male sibling had similar features with oculomotor apraxia. The RARS2 gene mutation can present with myoclonic epilepsy, mental retardation, and pyramidal and extrapyramidal features, and is an important differential for causes of progressive myoclonic epilepsy.

Entities:  

Keywords:  Extrapyramidal features; Mental retardation; Myoclonic epilepsy; RARS2 gene; Spasticity

Year:  2018        PMID: 29881806      PMCID: PMC5983106          DOI: 10.1002/epi4.12108

Source DB:  PubMed          Journal:  Epilepsia Open        ISSN: 2470-9239


RARS2 gene mutation can result in myoclonic epilepsy, mental subnormality, spasticity, and extrapyramidal features like bradykinesis and dystonia RARS2 gene–related myoclonic epilepsy is an important differential for causes of progressive myoclonic epilepsy In all cases of infantile onset myoclonic epilepsy RARS2 gene mutation should be tested Pontocerebellar hypoplasia type 6 (PCH6), is an autosomal recessive mitochondrial disease caused by mutations in the RARS2 gene.1 The RARS2 gene encodes mitochondrial arginyl transfer RNA synthetase, an enzyme necessary for mitochondrial protein translation.2 PCH6 is typically characterized by pontine atrophy, vermian hypoplasia, infantile encephalopathy, generalized hypotonia, and intractable seizures.3 Herein we describe 2 siblings with novel homozygous missense mutations of the RARS2 gene that presented with myoclonic epilepsy, mental sub‐normality, oculomotor apraxia, spasticity, and dystonia without pontine or vermian hypoplasia.

Methods

Both siblings were born of a second‐degree consanguineous marriage (Figure 1). A detailed history was obtained and a routine physical examination was conducted. Extensive clinical and biochemical workup was performed, including tandem mass spectroscopy (TMS), and serum lactate and ammonia tests. Spasticity was graded using the modified Ashworth scale. Brain magnetic resonance imaging (MRI) and electroencephalography (EEG) were also performed. Next‐generation sequencing was carried out for genetic analysis. The complete list of clinical features of both siblings is summarized in Table 1.
Figure 1

Pedigree chart of the family showing the affected siblings and unaffected parents in a second‐degree consanguineous marriage

Table 1

Clinical features exhibited by the 2 siblings

Sibling 1Sibling 2
Age/sex24 year/Male20 year/Female
BirthDelayed cryUneventful
MyoclonusSince birthSince birth
Truncal and appendicularTruncal and appendicular
Action and sound sensitiveAction myoclonus
Improved with drugsPoor response
Falls due to jerksNo falls
Delayed milestonesPresentPresent
Febrile seizuresPresentPresent
Subnormal IntelligenceSevereModerate
Activities of daily livingDependentIndependent
Oculomotor apraxiaPresentAbsent
SpasticityPresentPresent
Ashworth score22
Spastic dysarthriaPresentPresent
DystoniaBradykinesia/dystoniaMild
TremorsPosturalPostural ‐ mild
GaitSpasticSpastic
MedicationsValproate, topiramateValproate, lamotrigine, zonisamide
FundusNo optic atrophy, retinitis pigmentosa, cherry red spot
HearingNormal
Pedigree chart of the family showing the affected siblings and unaffected parents in a second‐degree consanguineous marriage Clinical features exhibited by the 2 siblings

Genetics

Whole‐exome sequencing

DNA from the proband (Patient 1) was extracted from blood using standard protocol. Sequencing was performed on Illumina HiSeq 2500 using 100x2 V4 kit chemistry with an average sequencing depth of about 100X. Human reference genome GRCh37 was used for alignment. Genome Analysis Tool Kit was used for variant calling. International Haplotype Map Project, 1000 Genomes Project, Online Mendelian Inheritance in Man, data base for non synonymous single‐nucleotide polymorphisms functional prediction, Polymorphism Phenotyping, Catalogue Of Somatic Mutations In Cancer, and Clinically important Variants database were used for variant filtration and annotation. Further classification, annotation, and clinical interpretation was carried out using InterpretOmics database developed by manually curating clinical grade variant information from PubMed and other published data sources.

Sanger sequencing

High‐quality DNA was extracted from the blood of the proband, her sibling, and parents using standard protocol. Primers were designed for the identified variant. DNA was then subjected to bidirectional Sanger sequencing to screen the variants in RARS2 gene using ABI Prism 3730 Genetic Analyzer. Human reference genome GRCh38 was used for alignment.

Results

Patient 1

A 20‐year‐old woman had an uneventful full‐term birth; however, myoclonic jerks were noted immediately after birth. The patient had a history of multiple attacks of simple febrile seizures during childhood. Motor and mental milestones were delayed. The patient currently has mild mental sub‐normality but is independent in activities of daily living. On physical examination, the patient was found to have spastic dysarthria, postural tremors, bradykinesia, spasticity, and an axial and appendicular myoclonus precipitated by movement and sound (action and audiogenic). Deep tendon reflexes were brisk on both sides with extensor plantar response. MRI of the brain was normal. EEG showed diffused slowing. TMS, and serum lactate and ammonia levels were normal. The patient was treated with valproate, levetiracetam, and topiramate previously, but myoclonic jerks were poorly controlled.

Patient 2

A 24‐year‐old man, brother of Patient 1, had myoclonic jerks involving all 4 limbs detected immediately after birth. The patient had a history of multiple attacks of simple febrile seizures during childhood. All developmental milestones were delayed. The patient had severe mental sub‐normality, never attended school, and was dependent in all activities of daily living. On examination, the patient was found to have oculomotor apraxia, spastic dysarthria, action and audiogenic myoclonus, postural tremors, bradykinesia, dystonia of the limbs, and spasticity in all 4 limbs. Deep tendon reflexes were brisk on both sides with extensor plantar response. MRI brain was normal. EEG showed diffused slowing. TMS and serum lactate and ammonia levels were normal. The patient was treated with sodium valproate and topiramate, and myoclonic jerks were fairly controlled. Whole exome sequencing of the proband revealed a homozygous missense variant (c.848T>A; p.Leu283Gln) in exon 10 of the RARS2 gene, visualized on an integrated genomic viewer. The variant was noted across all reads of the sequencing run confirming homozygosity (Figure 2). In silico analysis models (Mutation Taster, Polymorphism Phenotyping v2, and Sorting Intolerant From Tolerant) predict this variant to be pathogenic. This missense variant was not noted previously in the 1000 Genomes Project. Orthogonal validation of the identified variant was performed using Sanger sequencing, and the presence of the variant was confirmed in a homozygous fashion. The unaffected parents and the affected sibling were also noted to have a heterozygous and homozygous copy of the variant, respectively, thus establishing a disease‐variant segregation in the current family (Figure 3).
Figure 2

Presence of mutation is seen across all reads of sequencing in an Integrated Genome Viewer

Figure 3

Representative image of electropherograms obtained on Sanger evaluation. 3A depicts a homozygous (T>A) variant in the gene noted both in the proband and the affected sibling. 3B depicts the heterozygous form of the same variant that was identified in both parents

Presence of mutation is seen across all reads of sequencing in an Integrated Genome Viewer Representative image of electropherograms obtained on Sanger evaluation. 3A depicts a homozygous (T>A) variant in the gene noted both in the proband and the affected sibling. 3B depicts the heterozygous form of the same variant that was identified in both parents

Discussion

RARS2 mutations were first described in 2007 in a Jewish family with severe infantile encephalopathy.4 Typically, mutations of RARS2 are characterized by neonatal lactic acidosis, intractable seizures, encephalopathy, hypotonia, spasticity, microcephaly, and profound developmental delay.3 Patients were found to have compound heterozygous mutations in a majority of the reported cases, whereas homozygous mutations have been reported in only 3 other families, apart from this case report.4, 5, 6 This missense variant has been reported previously in a compound heterozygous fashion in association with a 3 base‐pair deletion in siblings affected with PCH6.7 To the best of our knowledge, there have been 29 cases of PCH6 reported from 15 families.1 Compared to patients with classical PCH6, our patients had a milder phenotype and survived well into adulthood. Furthermore, no abnormalities such as pontine or vermian hypoplasia were detected through neuroimaging. Action and audiogenic myoclonus, postural tremors, oculomotor apraxia, spasticity, and dystonia were atypical features in these patients that have not been previously reported in PCH6. The association of myoclonic epilepsy with a RARS2 mutation is novel and has not been reported previously. The features of RARS2‐associated myoclonic epilepsy and other progressive myoclonic epilepsies have been compared in Table 2. Infantile onset may be an important clue to the diagnosis of RARS2‐associated myoclonic epilepsy.
Table 2

Comparison of myoclonic epilepsy due to RARS2 mutation with other progressive myoclonic epilepsies8

Age of onset (Vein)InheritanceProminent seizuresCerebellar signsDementiaFundusDysmorphismEEGMRIOther features
RARS2BirthAR

Myoclonus

Febrile seizures

Mental retardationNormalNoDiffuse slowingNormalOculomotor apraxia, EPS, spasticity and mental retardation
Unverricht‐Lundborg disease6–15AR Stimulus‐sensitive myoclonus GTCS Mid and lateMild and late/absentNormalNoGeneralized spike‐wave, poly‐spike discharges with photosensitivityNormalMost common PME
Lafora disease12–17AR

Stimulus sensitive myoclonus

Occipital seizures

EarlyEarly and relentlessNormalNoDisorganized with generalized high‐voltage spike‐wave dischargesDiffuse cortical atrophyEarly emotional disturbance death within 10 years of onset
Myoclonic epilepsy with ragged red fibersAny ageMitochondrialMyoclonusVariableVariableOptic atrophy/ retinopathy +/−+/−Generalized spike wave discharges at 2‐5 HzAtrophy with basal ganglion calcificationRagged red fibers in muscle biopsy, neuropathy, hearing lots
Neuronal ceroid LipofuscinosisVariableAR/ADVariableVariableRapidly progressiveMacular degeneration and visual failureNoBackground disorganization with generalized epileptiform dischargesAtrophy5 types, psychosis, hallucinations. early death and visual loss may be seen
SialidosisVariableARIntention and action myoclonusSecond or third decadeType I‐absent Type II – learning difficultyCherry red spotType II ++Low‐voltage fast activityAtrophy in late stagesHepatosplenomegaly, recurrent respiratory infections

AD, autosomal dominant; AR, autosomal recessive.

Comparison of myoclonic epilepsy due to RARS2 mutation with other progressive myoclonic epilepsies8 Myoclonus Febrile seizures Stimulus sensitive myoclonus Occipital seizures AD, autosomal dominant; AR, autosomal recessive.

Conclusion

This case report expands on the clinical spectrum of RARS2 mutations to include myoclonic epilepsy, spasticity, bradykinesia, dystonia, and oculomotor apraxia, in addition to the classical features. In patients of myoclonic epilepsy with atypical features, clinicians should test for RARS2 mutations.

Disclosure

We have no conflict of interest to declare. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines

Financial disclosure

None.
  8 in total

Review 1.  Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects.

Authors:  Amre Shahwan; Michael Farrell; Norman Delanty
Journal:  Lancet Neurol       Date:  2005-04       Impact factor: 44.182

2.  Novel mutations in WWOX, RARS2, and C10orf2 genes in consanguineous Arab families with intellectual disability.

Authors:  Asem M Alkhateeb; Samah K Aburahma; Wesal Habbab; I Richard Thompson
Journal:  Metab Brain Dis       Date:  2016-04-28       Impact factor: 3.584

3.  A novel mutation in the promoter of RARS2 causes pontocerebellar hypoplasia in two siblings.

Authors:  Zejuan Li; Rhonda Schonberg; Lucia Guidugli; Amy Knight Johnson; Stephen Arnovitz; Sandra Yang; Joseph Scafidi; Marshall L Summar; Gilbert Vezina; Soma Das; Kimberly Chapman; Daniela del Gaudio
Journal:  J Hum Genet       Date:  2015-03-26       Impact factor: 3.172

4.  Pontocerebellar hypoplasia type 6 caused by mutations in RARS2: definition of the clinical spectrum and molecular findings in five patients.

Authors:  Denise Cassandrini; Maria Roberta Cilio; Marzia Bianchi; Mara Doimo; Martina Balestri; Alessandra Tessa; Teresa Rizza; Geppo Sartori; Maria Chiara Meschini; Claudia Nesti; Giulia Tozzi; Vittoria Petruzzella; Fiorella Piemonte; Luigi Bisceglia; Claudio Bruno; Carlo Dionisi-Vici; Adele D'Amico; Fabiana Fattori; Rosalba Carrozzo; Leonardo Salviati; Filippo M Santorelli; Enrico Bertini
Journal:  J Inherit Metab Dis       Date:  2012-05-08       Impact factor: 4.982

5.  Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia.

Authors:  Simon Edvardson; Avraham Shaag; Olga Kolesnikova; John Moshe Gomori; Ivan Tarassov; Tom Einbinder; Ann Saada; Orly Elpeleg
Journal:  Am J Hum Genet       Date:  2007-08-24       Impact factor: 11.025

6.  Novel homozygous RARS2 mutation in two siblings without pontocerebellar hypoplasia - further expansion of the phenotypic spectrum.

Authors:  S Lühl; H Bode; W Schlötzer; M Bartsakoulia; R Horvath; A Abicht; M Stenzel; J Kirschner; S C Grünert
Journal:  Orphanet J Rare Dis       Date:  2016-10-21       Impact factor: 4.123

7.  Neuropathologic Characterization of Pontocerebellar Hypoplasia Type 6 Associated With Cardiomyopathy and Hydrops Fetalis and Severe Multisystem Respiratory Chain Deficiency due to Novel RARS2 Mutations.

Authors:  Nichola Z Lax; Charlotte L Alston; Katherine Schon; Soo-Mi Park; Deepa Krishnakumar; Langping He; Gavin Falkous; Amanda Ogilvy-Stuart; Christoph Lees; Rosalind H King; Iain P Hargreaves; Garry K Brown; Robert McFarland; Andrew F Dean; Robert W Taylor
Journal:  J Neuropathol Exp Neurol       Date:  2015-07       Impact factor: 3.685

8.  RARS2 mutations in a sibship with infantile spasms.

Authors:  Adeline Ngoh; Jose Bras; Rita Guerreiro; Esther Meyer; Amy McTague; Eleanor Dawson; Kshitij Mankad; Roxana Gunny; Peter Clayton; Philippa B Mills; Rachel Thornton; Ming Lai; Robert Forsyth; Manju A Kurian
Journal:  Epilepsia       Date:  2016-04-08       Impact factor: 5.864

  8 in total
  3 in total

1.  A Patient with a Novel RARS2 Variant Exhibiting Liver Involvement as a New Clinical Feature and Review of the Literature.

Authors:  Selin Sevinç; Aslı İnci; Fatih S Ezgü; Fatma T Eminoğlu
Journal:  Mol Syndromol       Date:  2022-02-01

2.  Infantile-onset myoclonic developmental and epileptic encephalopathy: A new RARS2 phenotype.

Authors:  Guillem de Valles-Ibáñez; Michael S Hildebrand; Melanie Bahlo; Chontelle King; Matthew Coleman; Timothy E Green; John Goldsmith; Suzanne Davis; Deepak Gill; Simone Mandelstam; Ingrid E Scheffer; Lynette G Sadleir
Journal:  Epilepsia Open       Date:  2021-11-18

3.  Biomarker discovery in attention deficit hyperactivity disorder: RNA sequencing of whole blood in discordant twin and case-controlled cohorts.

Authors:  Timothy A McCaffrey; Georges St Laurent; Dmitry Shtokalo; Denis Antonets; Yuri Vyatkin; Daniel Jones; Eleanor Battison; Joel T Nigg
Journal:  BMC Med Genomics       Date:  2020-10-28       Impact factor: 3.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.